EC Number   |
Inhibitors |
Structure |
|---|
    2.4.2.17 | (4E)-4-[(4-chlorophenyl)(hydroxy)methylidene]-1-(pyridin-3-ylmethyl)-5-(3,4,5-trimethoxyphenyl)pyrrolidine-2,3-dione |
binds to the cavity between the domains I and II. The terminal chlorobenzoyl group of 1 makes hydrophobic interactions with the amphiphilic pocket near the phosphoribosyl pyrophosphate binding site |
   |
| 2.4.2.17 | 1,2,4-Triazole-3-alanine |
- |
|
| 2.4.2.17 | 1-(5-phospho-alpha-D-ribosyl)-ATP |
product inhibition, competitive to both substrates |
|
| 2.4.2.17 | 1-(5-phospho-beta-D-ribosyl)-ATP |
product inhibition |
|
| 2.4.2.17 | 1-[(5,6-diphenyl-1,2,4-triazin-3-yl)sulfanyl]-3-(1,3-thiazol-2-yl)propan-2-one |
most potent inhibitor, spans the PR-ATP binding site, exhibits greater than 50% inhibition at 0.01 mM, 40% inhibition at 0.001 mM |
|
| 2.4.2.17 | 2-([7-[(3-hydroxyphenyl)amino]-4-nitro-2,1,3-benzoxadiazol-5-yl]amino)-5-nitrophenol |
exhibits 46% inhibition |
|
| 2.4.2.17 | 2-([7-[(3-hydroxyphenyl)amino]-4-nitro-2,1,3-benzoxadiazol-5-yl]amino)-5-nitrophenol |
has whole-cell activity at 0.012 mM |
|
| 2.4.2.17 | 2-methyl-L-histidine |
- |
|
| 2.4.2.17 | 2-thiazol-DL-alanine |
- |
|
| 2.4.2.17 | 2-[(2-bromo-3,5-dinitrophenyl)carbonyl]-N-phenylhydrazinecarboxamide |
exhibits 71% inhibition |
|
